Heart transplant patients get hepatitis c cure hope

NCT ID NCT03886077

Completed Disease control Sponsor: Sentara Norfolk General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a 12-week course of glecaprevir/pibrentasivir can safely cure hepatitis C in heart transplant patients who got the virus from infected donors. Fifty adults on the transplant waitlist were enrolled, and those who received a hepatitis C-positive heart were treated after infection was confirmed. The main goal was to see if the virus stayed gone 12 weeks after treatment, with a secondary check on heart artery health one year later.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: glecaprevir/pibrentasivir
What this could lead to: If successful, this could show that treating hepatitis C after heart transplant is safe and effective, potentially improving outcomes for patients who receive infected donor hearts.
What could go wrong: This is a small, early study with only 50 participants and no blinding, so results may not apply to everyone. The long-term effects on heart health are still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE MORALITY

Contacts and locations

Locations

Sentara Norfolk General Hospital

Norfolk, Virginia, 23507, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.